Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Eli Lilly

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loxo-305,Venetoclax,Rituximab

            Therapeutic Area: Oncology Product Name: LOXO-305

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Available

            Deal Size: Not Available Upfront Cash: Not Available

            Deal Type: Not Available November 05, 2020

            Details:

            LOXO-305 oral presentations will provide updated data from the ongoing Phase 1/2 BRUIN clinical trial in previously treated chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, and other non-Hodgkin lymphomas.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Infections and Infectious Diseases Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Available

            Deal Size: Not Available Upfront Cash: Not Available

            Deal Type: Not Available November 05, 2020

            Details:

            The Subject Expert Committee (SEC) that advises the drug regulatory authority on new drugs, vaccines for Covid gave its permission to the company in a meeting held on November 4.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NKTR-358

            Therapeutic Area: Immunology Product Name: LY3471851

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Nektar Therapeutics

            Deal Size: Not Available Upfront Cash: Not Available

            Deal Type: Not Available November 04, 2020

            Details:

            Initial data presented earlier this year at the EULAR 2020 showed that NKTR-358 was safe and well tolerated in patients with mild-to-moderate SLE and led to a marked and selective, dose-dependent expansion of Tregs that was maintained over multiple administrations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Incyte Corporation

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 31, 2020

            Details:

            New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FCN-338

            Therapeutic Area: Oncology Product Name: FCN-338

            Highest Development Status: Undisclosed Product Type: Small molecule

            Recipient: Fosun Pharmaceutical

            Deal Size: $440.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement October 30, 2020

            Details:

            Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and Hong Kong.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galcanezumab

            Therapeutic Area: Neurology Product Name: Emgality

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Daiichi Sankyo Europe

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 30, 2020

            Details:

            Under the terms of the agreement, Eli Lilly Japan will hold a marketing authorization for galcanezumab and Daiichi Sankyo will take charge of its distribution and sales after marketing approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Incyte Corporation

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ixekizumab

            Therapeutic Area: Dermatology Product Name: Taltz

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Taltz demonstrated sustained efficacy in adult psoriasis patients with baseline scalp, nail and palmoplantar (skin on the palms of the hands and soles of the feet) involvement with the following results at five years.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bamlanivimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: LY3819253

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            Data from the BLAZE-1 study show bamlanivimab may be effective in treating COVID-19 by reducing viral load, symptoms and the risk of hospitalization in patients recently diagnosed with mild to moderate COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bamlanivimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: LY-CoV555

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. government

            Deal Size: $375.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 28, 2020

            Details:

            The U.S. government will accept the vials of bamlanivimab if it is granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

            PharmaCompass